Skip to main content
Entheon Biomedical Corp. logo

Entheon Biomedical Corp. — Investor Relations & Filings

Ticker · ENBI ISIN · CA29383X2023 LEI · 894500N2J7IXCCDRWU50 CSE Professional, scientific and technical activities
Open in API
Filings indexed 369 across all filing types
Latest filing 2022-03-30 Regulatory Filings
Country CA Canada
Listing CSE ENBI

About Entheon Biomedical Corp.

https://www.entheonbiomedical.com/

Entheon Biomedical Corp. is a biotechnology research and development company focused on creating therapeutic solutions for addiction and substance use disorders. The company specializes in the development and commercialization of psychedelic medicines, particularly dimethyltryptamine (DMT). Entheon aims to progress psychedelics to therapeutics by engineering proprietary drug discovery platforms, innovative drug delivery systems, and novel compounds tailored for treating these complex conditions.

Recent filings

Filing Released Lang Actions
52-109FV1 - Certification of annual filings - CFO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a Form 52-109FV1, which is a certification of annual filings by a venture issuer's CFO. It certifies the review and fair presentation of the annual filings for the financial year ended November 30, 2021. The content is primarily an officer certification letter confirming the accuracy and completeness of the annual filings, without containing actual financial statements or detailed financial data. According to the Certification Rule, documents that are primarily officer certifications, even if referencing annual reports or filings, should be classified as Regulatory Filings (RNS). The document length is 3167 characters, which is relatively short and consistent with a certification letter rather than a full annual report. Therefore, the correct classification is Regulatory Filings (RNS).
2022-03-30 English
Annual MD&A - English.pdf
Management Reports Classification · 100% confidence The document is titled 'Management Discussion and Analysis' (MD&A) for the fiscal year ended November 30, 2021, prepared by Entheon Biomedical Corp. It contains detailed management commentary on the company's financial position, results of operations, business overview, corporate structure, and forward-looking statements. The document references audited consolidated financial statements and provides substantive financial and operational analysis. The length of the document (15,000 characters) and the detailed content confirm it is a full management report rather than a brief announcement or certification. Therefore, this document fits the category of Management Reports (MDA), which provide management's detailed explanation of financial results, business trends, and outlook.
2022-03-30 English
Audited annual financial statements – English.pdf
Audit Report / Information Classification · 95% confidence The document is titled 'Consolidated Financial Statements for the years ended November 30, 2021 and 2020' and includes an Independent Auditors' Report. It contains detailed financial statements such as the Consolidated Statements of Financial Position, Comprehensive Loss, Changes in Equity, and Cash Flows. The presence of an auditor's opinion and detailed financial data for a full fiscal year indicates this is a full annual financial report. The document is about 15,000 characters long, which is consistent with a full report rather than a brief announcement. There is no indication that this is merely an announcement or certification. Therefore, this document fits the definition of an Annual Report (10-K equivalent). FY 2021
2022-03-30 English
AB form 13-501F1 (class 1 and 3B reporting issuers - participation fee).pdf
Regulatory Filings Classification · 100% confidence The document is a Form 13-502F1 related to Class 1 and Class 3B reporting issuers and their participation fees, submitted to the Ontario Securities Commission. It includes a management certification by the CFO, market value calculations of securities, and fee calculations under OSC Rule 13-502. The content is primarily a regulatory form with certification and fee calculation details, not a financial report or earnings release. It is a regulatory filing related to compliance and fee reporting to a securities commission, not an annual report, audit report, or other financial statement. Therefore, it fits best under Regulatory Filings (RNS).
2022-03-30 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the expansion of a genetic test panel and a new clinical research platform by Entheon Biomedical. It also announces the securing of private loans and details about the loan terms and future financing plans. There are no financial statements, quarterly or annual results, or detailed financial analysis present. The content focuses on product development and financing updates rather than a formal financial report or regulatory filing. The document is not a full financial report, earnings release, or management discussion. It is an announcement of financing activity and product development, which fits best under Capital/Financing Update (CAP). The document length is 7,882 characters, which is substantial but the content is clearly an announcement rather than a full report. Therefore, the most appropriate classification is CAP with high confidence.
2022-03-29 English
Material change report - English.pdf
Capital/Financing Update Classification · 95% confidence The document is titled 'Form 51-102F3 Material Change Report' and discusses the filing of a final short form base shelf prospectus with Canadian securities commissions. It details the company's ability to make offerings of securities up to a certain amount over a 25-month period. The content focuses on a material change announcement related to capital raising and financing activities. There are no financial statements or detailed financial performance data, so it is not an Annual Report or Interim Report. The document is not a simple announcement of a report publication but a substantive regulatory filing about a material change. Given the focus on financing and capital structure changes, the document fits best under the category 'Capital/Financing Update (CAP)'. The document length is just under 5,000 characters, and it contains detailed information about the material change, not just a brief announcement, supporting this classification.
2022-03-16 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.